Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas

Table 2 The mean, SEM, and range of ages, KPS, response (PR/CR), and number of prior chemotherapies for the 16 groups*

	Age	KPS	PR+CR	Number of prior chemotherapies
				0	1	2	≥ 3
Mean	41	84	10%	2.5%	52%	34%	9%
SEM	0.7	0.5	2.2	1.8	6.0	4.7	2.3
Group ranges	36–47	80–88	0–33	0–24	10–100	0–69	0–26

*T-test comparisons for all variables among the 16 groups were not significantly different. KPS = Karnofsky performance score; PR = partial response; CR = complete response.

ISSN: 1471-2407